{"disease":{"id":"transthyretin-amyloid-cardiomyopathy","name":"Transthyretin Amyloid Cardiomyopathy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":3},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndaqel","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndamax","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"},{"drug_id":"treatment-for-ttr-amyloidosis","indication_name":"Transthyretin (TTR) Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment for TTR amyloidosis","generic_name":"treatment-for-ttr-amyloidosis","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n","quality_score":null,"revenue":null,"mechanism":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n"},{"drug_id":"tafamidis-61-milligrams","indication_name":"Transthyretin Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis 61 milligrams","generic_name":"tafamidis-61-milligrams","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Tafamidis 61mg as provided in real-world practice","quality_score":null,"revenue":null,"mechanism":"Tafamidis 61mg as provided in real-world practice"}],"offLabel":[],"totalMarketed":4,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07358078","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06338839","title":"Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia","phase":"","overall_status":"TERMINATED","enrollment_count":1770,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02791230","title":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1733,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07207811","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07052903","title":"TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04108091","title":"Vyndaqel Capsules Special Investigation (ATTR-CM)","phase":"","overall_status":"COMPLETED","enrollment_count":1214,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06183931","title":"Study of ALXN2220 Versus Placebo in Adults With ATTR-CM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1181,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06679946","title":"A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04153149","title":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":655,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT05489549","title":"Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT01994889","title":"Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":441,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06101108","title":"Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Philippe Debonnaire","has_results":false},{"nct_id":"NCT03997383","title":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":360,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT04424914","title":"Global Prevalence of ATTR-CM in Participants With HFpEF","phase":"NA","overall_status":"TERMINATED","enrollment_count":347,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07170306","title":"Cardiac Amyloidosis in Patients With Aortic Stenosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":143,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04801329","title":"Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05442047","title":"A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06338696","title":"Thailand ATTR-CM Registry","phase":"","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT05896904","title":"Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Aarhus University Hospital Skejby","has_results":false},{"nct_id":"NCT06260709","title":"A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT06194825","title":"EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04814186","title":"A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06393465","title":"Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07298044","title":"A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06539208","title":"A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"YolTech Therapeutics Co., Ltd","has_results":false},{"nct_id":"NCT04622046","title":"A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06372301","title":"Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT05233163","title":"SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT07448623","title":"A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06321523","title":"A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","phase":"","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05139680","title":"A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05210010","title":"A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting","phase":"NA","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"Ensho Health Intelligent Systems Inc.","has_results":false},{"nct_id":"NCT06086353","title":"A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India","phase":"","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04899180","title":"Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05259072","title":"carDIo-ttranSSfOrm nucLEar Imaging Study","phase":"","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07494656","title":"A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05505838","title":"Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}